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Much of the current information regarding the 
function and characteristics of human lymphoid 
cells has been derived from studies of lymphocytes 
from other mammalian and avian species and from 
patients with immunodeficiency and other dis-
eases [1-4]. These data collectively provide a basis 
for subdividing human lymphocytes into two major 
groups according to their origin and function: 
thymus-derived (T) lymphocytes and bursa- or 
bone marrow-derived (B) lymphocytes. While inci-
sive studies of the function of different lymphocyte 
subpopulations have been possible in animals 
through ablation experiments and other manipula-
tions of the immune system, a majority of the 
functional studies in man have been based on in 
vitro investigations of lymphocytes from human 
"experiments-of-nature" where, with rare excep-
tion, the primary biologic errors are unknown [3]. 
Caution should be exercised in drawing conclu-
sions from much of the latter work, since recent 
studies in immunodeficiency patients have demon-
strated disparities between results of tests enumer-
ating blood cells with T - and B-lymphocyte differ-
entiation markers and results of tests of lym-
phocyte function [5-9]. Nevertheless, the generali-
zation can be made that functions of lymphoid 
subpopulations in man are probably roughly simi-
lar to those in other mammals and in birds. 
T-lymphocytes mediate delayed type skin reac-
tions, contact . hypersensitivity, allograft rejection, 
and graft-versus-host disease and manifest sup-
pressor activities for other T -lymphocytes and for 
B-cells; they also cooperate with B-cells in the 
immune response [10-12]. T -cells perform these 
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functions without any apparent endogeneous syn-
thesis or release of antibody, although they. do 
produce and elaborate the chemical mediators 
described in detail by Rocklin [13]. With the 
cooperation of T -lymphocytes and macrophages, 
B-lymphocytes differentiate into antibody-produc-
ing plasma cells that secrete antigen-specific im-
munoglobulin molecules into body fluids [14-16]. 
Methods for detecting and enumerating human 
peripheral blood T - and B-lymphocytes were de-
veloped in the early 1970s [17-21], after the discov-
ery of similar methods in lower species [22-24]. 
These methods are based on certain well-defined 
membrane characteristics of human T - and B-
cells. B-Iymphocytes bear easily detectable mem-
brane-associated immunoglobulin molecules that 
can be demonstrated using fluorescein-conjugated 
anti-immunoglobulin reagents [18,22]. Although 
some evidence exists that T -lymphocytes may also 
bear surface immunoglobulin [25,26], the extreme 
difficulty in detecting it on these cells makes the 
technique of membrane immunofluorescence quite 
useful in distinguishing B-lymphocytes in lymph-
oid cell populations. B-cells also have surface 
receptors for C3b and C3d fragments and for the 
fourth component of complement [2,27,28] and can 
be detected by rosette formation studies using 
antibody and complement-coated erythrocytes as 
indicators [2, 23]. Receptors for the Fc portions of 
IgG molecules are also present on B-Iymphocytes, 
although the question has been raised whether the 
cells with these receptors represent a distinct third 
population of lymphoid cells [29,30]. The latter 
cells lack surface immunoglobulin and C3b recep-
tors, fail to form sheep erythrocyte rosettes, and 
can be detected by rosette formation studies em-
ploying human erythrocytes coated with either 
human or heterologous IgG (HEA) [31]. Fluore-
scein-conjugated heat-aggregated IgG has also 
been used to detect human B-cells [32], but there 
is some evidence that the B-cell receptor for 
heat-aggregated IgG may be distinct from the 
aforementioned Fc receptor detected with the HEA 
indicator [33]. It has also been shown that some 
T -cells have receptors for aggregated IgG [34-36], 
thus putting in question the usefulness of this test 
for distinguishing the two major subpopulations. 
In the mouse, T -cells can be distinguished by e 
antigens found on their surfaces [24]; no antigen 
analogous to e has been adequately defined on 
human T -cells, although a number of antisera 
reportedly specific for human T -lymphocytes have 
been described [37-39]. The latter have been used 
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in cytotoxicity tests to estimate the number of 
T -cells present in human peripheral blood and 
lymphoid tissues. The most useful method for 
detecting and enumerating human T -lymphocytes 
is based on the chance observation that sheep 
erythrocytes form rosettes with human T -cells via 
a membrane receptor apparently present only on 
T -cells and probably on all such cells [17-20]. 
Populations of peripheral blood lymphocytes ex-
hibiting sheep erythrocyte rosette formation and 
those bearing the complement receptor or easily 
det~ctable surface immunoglobulin have been 
sho~ to be mutually exclusive [20], although, as 
stated above, this is not the case for some cells 
bearing receptors for aggregated IgG [35]. 
The term "null" has been used to describe those 
lymphocytes that cannot be detected by any of the 
above-mentioned techniques. Whether such cells 
actually exist or are a reflection of insensitivity of 
methods for detecting and enumerating T - and 
B-cells is a controversial issue; moreover, if they do 
exist, the question has arisen as to whether they 
represent undifferentiated pluripotential "stem" 
cells or just less mature versions of cells already 
destined to be T- or B-Iymphocytes. In favor of the 
latter are studies by Chess et al [40] who found 
that a population of lymphocytes bearing neither 
surface immunoglobulin nor receptors for sheep 
erythrocytes, but containing cells with the C3b 
receptor, developed surface immunoglobulin after 
2 to 3 days in culture. 
Another means of distinguishing lymphocyte 
sub populations is through their in vitro responsive-
ness to certain mitogenic agents or to allogeneic 
cel1s, through their activities in non-antibody-
dependent or antibody-dependent lymphocyte cy-
totoxicity assays, and through immunoglobulin 
biosynthetic studies. Soluble phytohemagglutinin 
(PHA) and concanavalin A (Con-A) both have 
been considered to stimulate predominantly T-
cells [41], although new evidence has been pre-
sented that casts some doubt on this conclusion 
[42]. In addition, recent studies in the mouse [43] 
and in man [44] indicate that PHA and Con-A may 
stimulate different subpopulations of T -cells. 
Pokeweed mitogen (PWM) has been shown to 
stimulate both human T - and B-cells, although 
low doses appear to stimulate B-cells preferentially 
[45]. In the in vitro response to allogeneic cells, 
only T -cells have been found to act as responders 
[46], whereas it appears that both T - and B-cells 
can stimulate [47]. T -cells have been shown to be 
killer cells in non-antibody-dependent cytotoxicity 
tests in vitro [48,49], whereas non-immuno-
globulin-bearing but Fc receptor-bearing (K) cells 
have been shown to be the effector cells in similar 
but antibody-dependent in vitro assays [30,50-52]. 
Finally, in in vitro immunoglobulin biosynthetic 
studies of mixed populations of human T - and 
B~cells cultured in the presence of PWM, only 
B-'lymphocytes differentiate into immunoglobulin 
synthesizing and secreting cells [14,15]. 
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It can be seen from the above that the evaluation 
of numbers and functions of human lymphocyte 
sub populations is complex; the results of such 
studies have been confusing, and conflicting data 
have appeared in the many published reports 
dealing with such studies. Technical difficulties 
and variations account to a large extent for these 
discrepant findings. In this paper the various 
methods noted above will be described only briefly, 
but the major technical pitfalls will be noted for 
each. More detailed information can be found in 
the paper by Aiuti et al [21]. 
DETECTION AND ENUMERATION OF B-CELLS 
A major problem with all tests quantifying 
peripheral blood B-Iymphocytes in mixed cell 
populations arises from the fact that monocytes 
also have both Fc and C3b receptors. Although 
methods have been described for monocyte deple-
tion [53,54] or their more precise identification 
[55,56], the cell yields are often low in the former 
situation, resulting in selective losses of either T-
or B-cells, and few of the latter identification 
methods ensure detection of promonocytes. The 
most promising of these appears to be the peroxi-
dase method [56]. 
Membrane Immunofluorescence Studies 
These studies are carried out by mixing purified 
peripheral blood lymphocytes with fluorescein-iso-
thiocyanate conjugated (FITC) antisera specific 
for the heavy chains of the different immunoglobu-
lin classes or for either kappa or lambda light 
chains, or with an anti-FAB reagent that detects 
both types of light chains [18]. It is important that 
these studies be carried out at 4°C on living cells 
and in the presence of 0.02% sodium azide in order 
to prevent capping of surface immunoglobulin. Rel-
atively high fluorescein to protein molar ratios (i.e., 
2: 1 to 4: 1) and an epi-illuminated microscope give 
the clearest membrane fluorescence, since positive 
cells usually show a finely granular staining pattern 
allover the cell surface. Winchester et al [35] have 
recently demonstrated important technical prob-
lems in the use of this assay. These occur primarily 
due to the presence of Fc receptor-bearing lympho-
cytes, monocytes, and/or promonocytes in the cell 
populations being tested; such cells may have IgG 
antibody-antigen complexes bound to the Fe recep-
tors and/or aggregated IgG in the fluoresceinated 
reagent may bind, giving false positive results. In 
studies where lymphocytes were treated with pro-
teolytic enzymes to remove surface immunoglobu-
lin and the cells allowed to resynthesize immuno-
globulin, only IgM- and IgD-bearing cells could be 
detected. In addition, only surface IgM and IgD 
were found if F(ab') 2 anti-heavy-chain reagents 
were employed in the routine assay. It has been 
shown that most (75-86%) peripheral blood lym-
phocytes bearing IgD also bear IgM, i.e., are 
double producers [57]. The mean percentage of all 
immunoglobulin-bearing cells detected by Win-
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chester et al [35] by a mixed F(ab') 2 anti-IgM and 
anti-IgD reagent in 8 normal subjects was 5.9%, 
far less than the normal means of total immunoglob-
ulin-bearing cells cited in most published reports, 
which range from 20 to 30% [21]. 
Rosette Formation with Complement-Coated 
Erythrocytes 
In most reports these tests have been carried 
out with sheep erythrocytes coated with rabbit 
antibody and mouse complement [2, 23]. A rosette 
is usually defined as a lymphocyte binding three or 
more erythrocytes. The percentage of normal pe-
ripheral blood complement receptor lymphocytes 
(CRL) detected by this assay in most laboratories 
approaches 15% [21]. Caution must be taken to 
carry out the incubation at 37°C when sheep 
erythrocytes are used, however, to avoid falsely 
high percentages, since coating sheep cells with 
antibody and complement does not cover determi-
nants that bind to human T-Iymphocytes when the 
test is conducted at lower temperatures [20]. Al-
ternatively, the problem can be circumvented by 
using human erythrocytes coated with a rabbit IgM 
antihuman erythrocyte antibody and/or a human 
IgM cold agglutinin and human or mouse comple-
ment (HEAC). It should be recognized, however, 
that use of human complement results in red blood 
cell binding of predominantly the C3b fragment 
[28], whereas use of mouse complement results in 
red blood cell binding of mainly the C3d fragment. 
Tests for Aggregated IgG (Agg-IgG) Binding Cells 
These tests are carried out with Cohn fraction II 
IgG that is fluorescein-conjugated, heated to 63°C 
for 15 min, and centrifuged at high speed to remove 
large aggregates [32]. A World Health Organiza-
tion Committee examining technical aspects of 
human T- and B-cell enumeration found the mean 
percentage from seven laboratories of peripheral 
blood lymphocytes binding FITC Agg-IgG to be 
17.2%. Although cells binding FITC Agg-IgG were 
initially thought to be the same as cells binding 
erythrocyte-bound IgG, as noted above recent evi-
dence indicates that they are two distinct subpopu-
lations [31] and some cells forming sheep erythro-
cyte rosettes have also been noted to bind FITC 
Agg-IgG [35]. 
Rosette Formation with IgG-Coated Human Eryth-
rocyte Indicators 
In these studies, human erythrocytes are coated 
with either human or rabbit IgG antibodies directed 
to red cell antigens; they are then mixed with 
macrophage-depleted purified lymphocyte sus-
pensions and examined for rosette formation as de-
fined above. Using such assays, the percentages of 
peripheral blood lymphocytes detected in several 
laboratories ranged from 5 to 1.0% when human red 
blood cells coated with Ripley incomplete anti-D 
antibody were used [21] and were 6.23 ± 4.07% 
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when human red blood cells coated with rabbit 
antibody were used (Gilbertsen and Metzgar, un-
published data). The large differences l;>etween 
percentages of cells detected with these indicators 
and the percentage obtained with FITC Agg-IgG 
reagents are further evidence for the likely involve-
ment of separate receptors in these two types of 
assays. 
DETECTION AND ENUMERATION OF T-CELLS 
Spontaneous Sheep Erythrocyte (E) Rosette 
Studies 
In this assay, sheep erythrocytes are mixed with 
purified populations of human peripheral blood 
lymphocytes in a ratio of 50-100: 1, centrifuged at 
200 g at room temperature, then incubated for 1 hr 
at room temperature before being gently resus-
pended and examined for rosette formation [20]. 
Using this method, greater than 90% of human 
thymocytes and 50 to 60% of peripheral blood 
lymphocytes form rosettes. The addition of protein 
to the medium increases the stability of the 
rosettes. Care must be taken to avoid extreme 
incubation temperatures, as the rosettes dissociate 
at 0° or 37°C [20]. More recently, this assay has 
been modified to increase both the stability and 
the percentage of T -lymphocytes detected by an 
average of 20% more (i.e., to 75%) by pretreatment 
of the sheep erythrocytes with neuraminidase (En) 
[58]. That the additional cells detected are T -cells 
has been shown by CRL rosette depletion studies 
that failed to alter the absolute number of En 
binding cells. As already mentioned, however, 
some En rosette-forming cells do bind FITC 
Agg-IgG; in addition, a small percentage (2-3%) of 
E-rosetting cells in normal subjects have been 
found to have surface immunoglobulin by FITC 
whole anti-immunoglobulin reagents [34] or to 
bear the complement receptor [59]. Another modi-
fication of the E rosette test, employing a shorter 
incubation time, is claimed to identify only "ac-
tive" rosette-forming T -cells [60]; the significance 
of these cells remains to be established. 
Cytotoxicity Tests with Anti-T Cell Antisera 
These assays are limited by the specificity of the 
antisera. Since few reagents have been produced 
that demonstrate reciprocity with tests to detect 
and enumerate B-cells [37-39], this method is not 
widely employed for quantifying T -cells." 
FUNCTIONAL STUDIES 
Responses of Lymphocytes to Mitogens and to 
Allogeneic Cells 
These studies are quite useful in distinguishing 
severe combined immunodeficiency disease 
(SCID) from other forms of immunodeficiency but 
help very little in distinguishing the other cate-
gories of immune disorders. The primary reason for 
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this is that there is marked day-to-day and sub-
ject-to-subject variability in results of lymphocyte 
stimulation studies. In addition, there is considera-
ble variability in responsiveness of the lympho-
cytes from the same subject with time and with 
respect to the optimal dose of stimulant and time 
of harvest. We have found it necessary to do 
time-course and dose-response studies in each 
evaluation in order to obtain any meaningful data. 
A microtiter plate modification of these methods 
has made these studies possible even on reasonably 
small volumes of blood and also permits more 
replicates. The several sources of variability lead to 
large standard deviations and wide 95 % confidence 
intervals on pooled normal data. In addition, data 
from such studies have a logarithmic Gaussian 
distribution and so must be converted to logs for 
statistical analysis. 
Non-Antibody-Dependent Killer Cell Assays 
These studies are carried out by mixing purified 
immune or mixed lymphocyte reaction (MLR)-
stimulated lymphocytes with 51Cr-labeled target 
lymphocytes or monolayers in varying ratios and 
measuring the amount of 51Cr released over that 
spontaneously released in cultures without immune 
lymphocytes [48]. The data are expressed as a per-
centage of the total 51Cr bound to the targets. This 
activity is mediated,only by immune T-lymphocytes 
[4(\ ]. ·iI 
Antibody-Dependent Killer Cell Assays 
In these experiments, macrophage-depleted, 
Ficoll-purified, nonimmune human lymphocytes 
are mixed with 51Cr-labeled target lymphocytes, 
erythrocytes, or tumor cells in the presence of 
heat-inactivated (56°C for 30 min) antitarget anti-
body. Following incubation the amount of specific 
51Cr released is determined as above, after sub-
tracting the amount of 51Cr released in cultures 
without effector lymphocytes [61]. This activity 
has been shown to be a property only of lympho-
cytes bearing the Fc receptor [30,50,52] and it does 
not require interaction with C3 [62]. 
Immunoglobulin Biosynthesis 
This can be studied in vitro by culturing washed 
human lymphocyte populations with PWM in 
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cultures supplemented with fetal calf serum; the 
amount of human immunoglobulin released in the 
culture supernatants 7 to 21 days later is quanti-
fied by double antibody radioimmunoassay [14]. 
Alternatively, unstimulated lymphocytes can be 
cultured in the presence of 3H_ or l4C-labeled 
amino acids and the labeled immunoglobulins 
measured by a solid phase radioimmunoassay [16]. 
Methods of these types have been extremely valua-
ble in the study of agammaglobulinemic patients 
with various types of B-cell maturational defects 
[15,63] or with defective immunoglobulin synthesis 
due to excess numbers of T -suppressor cells [14]. 
STUDIES IN PATIENTS WITH IMMUNODEFICIENCY 
After the above methodologies were developed, 
studies of lymphocytes from large numbers of 
patients with various types of immunodeficiency 
were carried out in many laboratories (see bibliog-
raphy of Schiff et al [6]). In most of these patients 
varying quantities of lymphocytes have been de-
tected by one or more of the above methods and, 
for the most part, the numbers detected fall within 
or close to the normal range. In addition, the 
responses to mitogens and allogeneic cells are 
usually within the normal range [6]. The excep-
tions to this statement are boys with X-linked 
agammaglobulinemia who have very low or no 
surface immunoglobulin-bearing B-lymphocytes, 
although they do have cells bearing the comple-
ment and Fc receptors [6,64], and infants with 
DiGeorge's syndrome (DiG) [65] and severe com-
bined immunodeficiency, who may have very low 
numbers of E-rosette-forming cells and absent or 
extremely low responses to mitogens and alloge-
neic cells [5]. 
The most important information has come, how-
ever, from those studies in which T - and B-cells are 
enumerated and their functions evaluated. 
Through such combined studies in our laboratory, 
we have observed unexpected disparities that may 
bear on the primary defects in certain of these 
deficiency states [5]. We have recently evaluated 3 
infants with severe combined immunodeficiency 
disease (SCID) and one with DiG and found 
varying proportions of peripheral blood cells with 
surface markers typical of T - or B-Iymphocytes in 
a114 infants (Tab. I). In 2 of the infants with SCID, 
TABLE I. T- and B-cells in the peripheral blood of 3 infants with severe combined immunodeficiency and of 1 with 
DiGeorge's syndrome 
Age Absolute % Ig-bearing B-cells % HEAC(B) % HEA(Fc) % E(T) % En(T) Case lymphocyte (mo) 
count/mm 3 G A M D E rosettes rosettes rosettes rosettes 
1 (SCID) 7 2,500 10 2.3 18.6 4.6 0.3 38.0 0 3.5 8.5 
2 (SCID) 12 2,376 53 36 54 69 1.6 81.0 4.0 1.0 6.0 
3 (SCID) 5 1/ 2 10,175 14 5 7 12 2.0 9.0 3.0 61.0 76.0 
4 (DiG) 3 2,500 58 4 42 31 1.8 27.0 38.0 16.0 35.0 
Normalsa 7,500 12.2 2.0 7.6 4.5 0.45 15.7 6.23 55.4 74.9 
( 4,000-10,500) ±6.1 ±1.7 ±3.0 ±3.6 ±O.66 ±5.6 ±4.07 ±8.9 ±6.2 
a See Buckley et al [5 J for sources of normal data for absolute lymphocyte counts and rosette studies. Normal data for membrane 
immunofluorescence studies have been reported previously by Schiff et al [6 J. 
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the percentages of B-cells were elevated and the 
percentages of T -cells very low; in the third, 
however, both the percentages and absolute num-
bers of both T - and B-cells were normal or near 
normal throughout a 4 1/2-month period of study. 
Despite this, functions mediated by T - or B-cells 
were either absent or very minimal in all 3 infants 
with SCID, including cell-mediated responses in 
vivo; in vitro proliferative response to mitogens, 
allogeneic cells, and antigens; effector cell function 
in lymphocyte antibody lymphocytolytic interac-
tion (LALI) assays; and in vitro synthesis of IgG, 
IgA, and IgM. Co-cultivation experiments with 
lymphocytes from 2 of these infants (Cases 2 and 3) 
and unrelated normal control lymphocytes failed to 
demonstrate suppressor cell activity for immuno-
globulin synthesis. A T-helper-cell defect was sug-
gested by results of cocultures with one of the in-
fants' cells and unrelated normal control cells, since 
immunoglobulin production was augmented 310 to 
560% over that expected on the basis of individual 
culture data. The finding of cells with differentia-
tion markers characteristic of T- and B-Iympho-
cytes in these 3 infants with SCID argues against 
the concept that this entity represents a stem cell 
defect. The data are rather more compatible with a 
block in maturation of cell function or a metabolic 
defect that prevents normally differentiated cells . 
from carrying out their functions. In contrast to the 
observations in the SCID patients, the results of 
functional studies in the DiG patient yielded just 
the opposite findings. Despite a very low percent-
age and low number of lymphocytes bearing T-cell 
differentiation markers, the infant's in vitro lym-
phocyte response to PHA was completely normal 
and better than that of the normal control's lym-
phocytes studied simultaneously; in addition, his 
cells gave significant though low responses to Con-
A and PWM and manifested normal LALI activity, 
and he had a normal delayed cutaneous response in 
vivo. Thus, though the defect in DiG resulted in far 
fewer than normal T-cells, the cells functioned quite 
normally. 
STUDIES IN PATIENTS WITH ATOPIC DERMATITIS 
Prompted by recent observations that the thy-
mus exerts an important regulatory influence over 
IgE antibody production in lower species, we 
conducted studies of immune function in 21 
patients with atopic eczema to seek evidence for a 
similar relation in man [66]. Paradoxically, while 
carrier-specific T -helper-cells appear to be neces-
sary for IgE antihapten antibody formation in 
rodents [67-70], carrier primed thymocytes have 
also been shown to have a potent inhibitory effect 
on IgE antibody production [68,71-73]. It is not 
known whether T -cells serve a similar regulatory 
function in man. Suggesting such a possibility is 
the finding that excessive IgE antibody production 
is associated with impaired cell-mediated immu-
nity in certain human immunodeficiency diseases. 
Conditions in which this has been observed include 
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the Wiskott-Aldrich, DiG, and Nezelof syndromes, 
and a recently described syndrome consisting of 
severe undue susceptibility to infection, exception-
ally high serum IgE concentrations, and impaired 
cellular immunity [74,75]. Serum IgE concentra-
tions are generally higher in patients with allergic 
eczema than in the other atopic states, hence we 
felt that the study of eczema patients might offer 
the greatest likelihood of observing any possible 
impairment in thymus-dependent immunity that 
may exist in atopy. The patients in this study were 
21 infants, children, and adolescents ranging from 
22 months to 17 years of age. In every case a 
diagnosis of atopic eczema was made on the basis 
of a focal or generalized macular and papular, 
lichenified, pruritic skin rash that showed predilec-
tion for the flexural areas of the extremities and/or 
the neck and face [76]. None of the patients was 
receiving systemic steroids at the time of this 
study, and only 6 had ever received such therapy . 
The subjects were divided into three categories 
based on the severity and distribution of their 
dermatitis. Group I included 12 patients with such 
severe generalized eczema that few areas of the 
head, trunk, or extremities were spared; Group II 
included 3 children whose eczematous lesions were 
confined primarily to localized areas of the extre-
mities and face, with little involvement of the 
trunk; and Group III was composed of 6 subjects 
with a past history of eczema but in whom only 
mild xerosis and lichenified patches remained in 
the flexural areas. 
Results of skin testing for delayed hypersensitiv-
ity to the ubiquitous antigens , Candida and SK-
SD, are given in Table II. The children with the 
most severe dermatitis (Group I) exhibited marked 
delayed cutaneous anergy; delayed cutaneous un-
responsiveness was also present in Group II chil-
dren who had localized eczema. In contrast, the 
children in Group III , who had nearly healed atopic 
dermatitis, all had positive delayed skin tests to 
one or both antigens. Serum IgE concentrations 
were markedly elevated in most subjects (Tab. III) 
and a correlation was noted between the extent of 
the dermatitis and the magnitude of the serum IgE 
concentration; concentrations of other immuno-
globulins were usually normal for age. Surpris-
ingly , despite the markedly elevated serum IgE 
concentrations, the percentages of IgE-bearing B-
lymphocytes were not elevated in these patients; 
the mean percentage of lymphocytes bearing IgD 
was, however, significantly greater (p .= .0392) 
than normal. These findings fail to support the 
observations reported by Cormane [77] and by 
Cormane et al [78]. 
Other immunologic abnormalities did not 
appear related to the severity of the eczema but 
pertained to the group as a whole. The mean 
percentage of CRLs (HEAC) was significantly (p = 
.0324) greater than in the control group (Tab. III). 
In contrast, the mean percentages of peripheral 
blood T -cells, as determined by spontaneous sheep 
erythrocyte formation and by rosette formation 
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TABLE II. Delayed skin test reactiuitya to Candida and SK-SD in 21 patients with atopic eczemab 
Other allergic Candida SK-SDe Patient Agee !Race/Sex diagnosesd 1:100 1:10 100/25 1000/250 
Group I-Generalized eczema 
JR 3/BIM A 
MT 3/BIM A,Ad 
BM 4/W/M A 
C8 5/BIM A 
RJ 6/W/M 
AP 7/W/F A 
8B 9/W/F A 
CJ 9/WIM A 
MF 9/W/F A 
RM 11/W/F A 
CQ 13/B/F A 
RA 14/WIM A,AR,Ad 
Group II-Localized eczema 
KM 2/B/M A 
. CR8 2/BIM 
RH 3/B/M 
Group III-Xerosis and lichenification only 
KT 4/BIM A + + 
YP 4/B/F + + 
AH 7/W/M AR + + 
8W 8/W/F AR + + 
LW 14/W/F AR + + 
8M 17/W/F A,AR + + 
a _ Denotes no reaction or <5 mm induration at 24,48, and 72 hr; + denotes reaction of induration 5 mm or greater 
in diameter at one or more of those times following testing. 
b Reprinted from J Allergy Clin Immunol 56:393, 1975 [66]. 
C Age in years 
d A = asthma, AR = allergic rhinitis, Ad = angioedema 
e Concentration per ml 
with neuraminidase-treated sheep erythrocytes, 
were significantly lower than in the normal con-
trols (p = < .0001, Tab. III). 
Data from in vitro lymphocyte stimulation stud-
ies are presented in Figures 1 and 2. The patient's 
geometric mean responses were lower than the 
geometric means of the normal control subjects for 
each of the three mitogens, PHA, Con-A, and 
PWM (Fig. 1). The differences between patient 
and control group means were statistically signifi-
cant only for Con-A (p = .0013) and PWM (p = 
.0002), however. In addition, the patient's geomet-
ric mean responses to the antigens, Candida albi-
cans extract and tetanus toxoid, were also lower 
than control group geometric mean responses to 
these two agents (Fig. 2). This difference was 
statistically significant only for Candida (p = 
.0017). 
Until recently, little was known about mech-
anisms involved in augmented IgE antibody pro-
duction. Important observations bearing on this 
were made by Tada and coworkers in 1971 when 
they showed that rat homocytotropic antibody 
responses were enhanced by treatment of such 
animals with small doses of antithymocyte serum, 
400-rad whole-body irradiation, adult thymectomy 
and splenectomy, or by giving various immunosup-
pressive drugs before or shortly after immunization 
[79-81]. The common facilitating factor in these 
treatments was revealed when these investigators 
found that administration of carrier-specific T-
lymphocytes could inhibit on-going hapten-spe-
cific homocytotropic antibody formation [71] . 
The delayed cutaneous anergy observed in these 
atopic eczema patients is consistent with an abnor-
mality in cellular immunity and is similar to that 
reported by Lobitz et al [82] who described 2 adults 
with life-long · atopic dermatitis who failed to 
respond at 48 hr to intradermal injections of a 
variety of ubiquitous bacterial and fungal antigens 
and failed to become sensitized to dinitro-
chlorobenzene (DNCB). The latter finding is in 
keeping with those of Palacios et al [83] and Jones 
et al [84], who found that patients with atopic 
dermatitis were less readily sensitized to DNCB 
and Rhus extract than were normals, and with 
those of Rostenberg and Sulzberger [85], who 
found a very low incidence of positive patch tests 
among eczema patients. The failure of the patients 
in the present study to respond to bacterial and 
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mycotic antigens would appear to be at variance 
with the results of Palacios et al [83], although, if 
reactions to Schick and Dick toxins and to mumps 
antigen are excluded from their results, only 19 of 
32 patients had positive delayed reactions; no 
information was given regarding the severity of the 
dermatitis in those patients. 
The finding of significantly lower percentages of 
T -lymphocytes in eczema patients in the present 
study is in keeping with a similar finding by 
Luckasen et al [86]. Grove et al [87], however, 
found no differences in absolute numbers of E 
rosetting or surface immunoglobulin-bearing cells 
when results in 35 eczema patients (mainly adults) 
were compared with those in controls, and PHA 
responses did not differ from controls. On the other 
hand, as in the present study, Grove and coworkers 
[87] did find significantly impaired delayed 
cutaneous responsiveness to bacterial, mycotic, 
and viral antigens and impaired antibody respon-
siveness following immunization with tetanus tox-
oid. These same workers had previously noted 
similar findings in a group of asthmatics, except 
that PHA responsiveness was also diminished in 
those patients [88] . The depressed cell-mediated 
immunity observed in these eczema patients may 
have some bearing on their known heightened 
TABLE III . Serum JgE and rosette formation data and 
statistical analyses comparing eczema patients and 
normalsa 
Study Popu- n Mean ± SD ph lation 
Ea 21 8.33 ± 1.360d 
IgE (4157) .0012 
ce 106 4.006 ± 1.207d 
(54.9) 
HEAC E 19 18.9 ± 6.7 .0324 C 39 15.1 ± 5.9 
HEA E 19 6.2 ± 6.6 .9678 C 13 6.2 ± 3.9 
E E 19 39.4 ± 12.7 < .0001 C 62 55.4 ± 9.0 
En E 19 60.9 ± 11.1 < .0001 C 17 75.9 ± 5.4 
a Reprinted from J Allergy Clin Immunol 56:393, 1975 
[66 ] 
b Calculated by the Mann-Whitney U test in the case 
of the IgE data and by Student's t-test in the case of all 
other data. 
C Eczema patients 
d IgE data expressed as mean ± SD of logarithms of 
data. Figures in parentheses are geometric means 
expressed as U Iml. 
e Controls 
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FIG. 1. Responses of atopic eczema patients' lympho-
cytes to mitogens. The data presented are the geometric 
means of results of quadruplicate cultures expressed in 
counts per minute per 105 lymphocytes "-nd represent the 
maximum responses obtained for patient or normal 
control lymphocytes. The geometric means of maximal 
responses in 129 PHA, 114 Con-A, and 109 PWM 
determinations on a normal population are shown by the 
solid horizontal lines, and the antilogs of the mean logs ± 
1 standard deviation of the logs of the data by the broken 
horizontal lines. Individual eczema patient values are 
depicted by the dots and the geometric means of all of the 
patients' responses are indicated by the horizontal 
arrows. The differences between the eczema patients' 
means and the normal Con-A and PWM means are 
significant at the p = .0013 and p = .0002 levels, 
respectively. 
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FIG. 2. Responses of atopic eczema patients' lympho-
cytes to antigens. See legend to Figure 1 for explanation 
of data presentation. The geometric means and standard 
deviations of maximal responses in 20 Candida and 18 
tetanus determinations on a normal population are 
shown by the horizontal solid and broken lines. The 
difference between the eczema patients' mean Candida 
response and that of the normals is significant at the p = 
.0017 level. 
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susceptibility to certain viral agents, namely vac-
cinia, herpes simplex, and molluscum contagiosum 
viruses [76]. Cell-mediated immunity is thought to 
play a major role in host defense against many 
viral infections. 
The reason for the greater impairment of cell-
mediated immunity in vivo than in vitro is not 
clear, although it suggests an abnormality in 
immune effector function rather than in the T-cell 
itself. In keeping with this, abnormalities in both 
polymorphonuclear [89] and mononuclear (Sny-
derman and Buckley, unpublished) chemotaxis 
have been observed in eczema patients. Finally, 
experimental work in lower species points to a 
deficiency ofT-suppressor-cells; it is not likely that 
the tests of T-cell function employed in this and 
other human studies would reflect a deficiency of 
this population of cells. Further studies with possi-
bly more appropriate assays will be required before 
definitive proof of abnormal T-cell function can be 
shown as a possible etiologic factor in the develop-
ment of atopic diseases. 
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DISCUSSION 
Austen: Is cutaneous anergy in atopic disease primary 
or secondary, that is, what happens with time and disease 
variability? What is the relation of the IgE level to the 
anergy state? 
Buckley: I can only speculate on the point but suspect 
that the anergy must be a secondary phenomenon . 
Although we are following the patients in Group I and II 
and hope to be able to reevaluate their cell-mediated 
immunity after they remit, we have no data from serial 
studies in the same patient as yet. The fact that all of the 
patients in Group III with the healed eczema responded 
with normal delayed hypersensitivity reactions is sugges-
tive of a disease-related or secondary effect. There was, as 
I pointed out, a rough correlation between both the serum 
IgE concentration and anergy and the extent of the 
dermatitis, but no definite correlation between the serum 
IgE level and anergy. 
Sams: Your data on the patients with generalized 
atopic dermatitis indicated that all but one of them also 
had asthma. Do you have studies on patients with only 
asthma or only atopic dermatitis? 
Buckley: You have put your finger on one of the major 
problems in trying to dissect out immunopathologic 
mechanisms in atopic dermatitis . It is extremely difficult 
to find infants and children with eczema who do not also 
have allergic rhinitis and/or asthma, particularly the 
latter. We have not conducted studies similar to the ones 
just described in patients who have only asthma. As 
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noted, however, Grove et al [J Allergy Clin Immunol 
55: 152, 1975] have also found impaired delayed cutane-
ous responsiveness to bacterial, mycotic, and viral anti-
gens, diminished PHA responsiveness, and impaired 
antibody responsiveness following immunization with 
tetanus toxoid in asthmatics, suggesting that the abnor-
malities may be present in aH atopics. 
Rocklin: I have three questions regarding your studies 
in patients with atopic dermatitis. First, do you have any 
data concerning the prior skin test reactivity of your 
patients before the onset of their skin disease? Second, do 
you have any in vitro evidence for the presence of 
blocking factors in the serum of these patients? Lastly, 
what is the nature of the chemotactic defect which you 
described? Does it involve a response of inflammatory 
cells to preformed chemotactic stimuli and/or the pro-
duction of a lymphocyte-derived chemotactic factor? 
Buckley: I have no observations on delayed skin tests 
in infants or children before the development of clinical 
atopy; there are studies going on at other centers where 
infants born to atopic parents are being followed by 
multiple immunologic parameters from birth onward, but 
I don't know of any of the results as yet. 
All of our lymphocyte cultures were conducted in 
media supplied both with autologous and AB-negative 
plasma from all male donors and in no instance was any 
evidence found of plasma blocking factors. 
We have looked for possible chemotactic defects in 
these patients but the findings have been inconsistent. 
These studies have been carried out by Dr. Ralph 
Snyderman at our institution. He has found some abnor-
malities of monocyte chemotaxis, both in the nature of 
intrinsic hyporesponsiveness of the cells and in the form 
of plasma inhibitors of monocyte chemotaxis . 
Cooper: Although the problem of cytophilic IgG raises 
the question of the presence of native IgG receptors on 
B-Iymphocytes, an abundance of evidence indicates that 
B-Iymphocyte precursors of IgG-secreting plasma cells 
may bear native IgG and/or IgM. 
The presence of cells with T-cell characteristics in your 
patient with the DiGeorge syndrome of course could have 
come from a small ectopic thymus which many such 
patients have been found to have. 
In your patient with nonfunctional T- and B-Iym-
phocytes, could these cells, like those from Kersey's 
patient, be activated by a calcium ionophore? 
Buckley: I also find it difficult to accept the point 
regarding the binding of fluorescein-conjugated heterolo-
gous IgG anti-immunoglobulin to the Fc receptor as being 
a major source of artifact, since with non-F (ab ')2 FITC 
anti-heavy chain reagents we get no binding to the 
lymphocytes of patients with X-linked agammaglobulin-
emia. Yet these patients have normal numbers of cells 
bearing the Fc receptor. 
Dr. Lischner pointed out at the Second Immunodefi-
ciency Workshop that, in reviewing autopsy material 
from DiGeorge patients at St. Christopher's, he had 
found small nests of thymic tissue in a majority of the 
cases and that the tissue appeared normal, i.e. , con-
tained both Hassall's corpuscles and thymocytes. I don't 
believe current textbooks and other literature adequately 
reflect that this is usually only a partial thymic defi-
ciency. This would certainly explain the spontaneous 
"cures" that have been noted in such patients. 
Our patient died before Dr. Kersey reported his 
observation on the effect of the calcium ionophore on the 
lymphocyte responsiveness of his patient. I agree that 
his patient's lymphocyte counts and sub population 
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findings were very similar to those in our Case 3. I would 
like to mention that, at postmortem examination of Case 
3, the thymus was extremely small and lacked Hassall's 
corpuscles and corticomedullary distinction, and there 
were no lymph nodes, follicles in the spleen, or gut-
associated lymphoid tissue. Therefore, we have wondered 
where all of the periph~ral blood lymphocytes were 
coming from. 
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Provost: Will preincubation of the peripherallympho-
cytes from atopic dermatitis patients prior to mitogenic 
stimulation increase their in vitro responsiveness? 
Buckley: We have not preincubated the cells but did 
wash them several times before resuspending them in 
media supplemented with AB-negative plasma from all 
male donors. The mitogens and antigens were added at 
time zero. 
